Metastatic Colorectal Cancers Completed Phase Trials for Bevacizumab (DB00112)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)CompletedNot Available
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02623621Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer
NCT01280643Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal CancerTreatment
NCT01437618First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer
NCT01533740Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients
NCT02612077Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)